Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


UIC researchers hunting drugs for devastating parasitic disease

Hundreds of millions of people, mainly in developing countries, are disabled by infectious diseases, according to the World Health Organization.

More than 12 million people in 88 countries are infected with leishmaniasis, a parasitic disease spread by the bite of infected sand flies. Nearly 2 million new cases are reported and about 70,000 people die from the disease annually.

Researchers at the University of Illinois at Chicago have discovered that compounds derived from a natural product can be used in developing a new drug to treat the disease.

Despite a worsening global impact of this disease, little progress has been made toward the development of new chemotherapeutics against it, says Alan Kozikowski, professor and director of UIC's Drug Discovery Program and coordinator of the project.

Drugs compounded from the toxic metal antimony have been the first-line therapeutic option for more than 50 years.

"But antimonials may cause acute pancreatitis and cardiac arrhythmia and can sometimes lead to death," Kozikowski said. Only recently, he said, have novel agents been added to the therapeutic arsenal.

Leishmaniasis can be cutaneus, which causes skin sores that leave ugly scars, or visceral, which is 100 percent fatal if left untreated.

Visceral leishmaniasis has increased in recent years due to emerging co-infections with HIV, spreading the disease to the developed countries in North America and southern Europe, Kozikowski said. The disease is normally found in tropical regions, from the rain forests in Central and South America to deserts in West Asia.

To find a starting point from which to develop a better drug, UIC postdoctoral researchers Suresh Tipparaju and Marco Pieroni synthesized a chemical "library" of more than 100 diverse compounds and screened them for biological activity against the Leishmania parasite. They observed high antiparasitic activity in a compound first isolated from streptomyces bacteria more than 20 years ago. That compound, Tipparaju said, could potentially be modified to treat leishmaniasis. It was already three times more active than miltefosine, a drug in current use, he said.

Miltefosine is the first oral drug to cure both visceral and cutaneus leishmaniasis. Despite the drug's efficacy, Tipparaju said, miltefosine is limited by its persistence in the bloodstream and long-term side effects. It is also not effective when given to patients co-infected with HIV.

The UIC researchers are attempting to develop an antiparasitic agent that is less toxic than miltefosine and that can kill the parasite inside blood cells. In addition, the researchers are investigating the mechanism of action of the new candidate compounds through a collaboration with Manlio Tolomeo of the Center for Parasitic Diseases in Palermo, Italy. Mechanistic studies could lead to further improvement of promising agents, Tipparaju said.

Sam Hostettler | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht Resolving the mystery of preeclampsia
21.10.2016 | Universitätsklinikum Magdeburg

nachricht New potential cancer treatment using microwaves to target deep tumors
12.10.2016 | University of Texas at Arlington

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>